Crinetics Pharmaceuticals (CRNX) Revenue & Revenue Breakdown
Crinetics Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$4.01M
Latest Revenue (Q)
$640.00K
Crinetics Pharmaceuticals Revenue by Period
Crinetics Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $4.01M | -15.28% |
| 2022-12-31 | $4.74M | 339.42% |
| 2021-12-31 | $1.08M | 1418.31% |
| 2020-12-31 | $71.00K | -94.05% |
| 2019-12-31 | $1.19M | -50.86% |
| 2018-12-31 | $2.43M | 18.73% |
| 2017-12-31 | $2.04M | 247.20% |
| 2016-12-31 | $589.00K | - |
Crinetics Pharmaceuticals generated $4.01M in revenue during NA 2023, up -15.28% compared to the previous quarter, and up 165.28% compared to the same period a year ago.
Crinetics Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $640.00K | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2023-09-30 | $346.00K | -64.98% |
| 2023-06-30 | $988.00K | -63.12% |
| 2023-03-31 | $2.68M | 277.86% |
| 2022-12-31 | $709.00K | 54.80% |
| 2022-09-30 | $458.00K | 4.33% |
| 2022-06-30 | $439.00K | -85.98% |
| 2022-03-31 | $3.13M | 190.45% |
| 2021-12-31 | $1.08M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $71.00K | -77.88% |
| 2019-12-31 | $321.00K | -36.44% |
| 2019-09-30 | $505.00K | 100.00% |
| 2019-06-30 | - | -100.00% |
| 2019-03-31 | $367.00K | -53.01% |
| 2018-12-31 | $781.00K | 42.52% |
| 2018-09-30 | $548.00K | -16.59% |
| 2018-06-30 | $657.00K | 48.64% |
| 2018-03-31 | $442.00K | -16.29% |
| 2017-12-31 | $528.00K | -17.50% |
| 2017-09-30 | $640.00K | -23.08% |
| 2017-06-30 | $832.00K | 1748.89% |
| 2017-03-31 | $45.00K | - |
Crinetics Pharmaceuticals generated $640.00K in revenue during Q1 2024, up 100.00% compared to the previous quarter, and up 90.27% compared to the same period a year ago.
Crinetics Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALEC | Alector | $97.06M | $15.89M |
| RGNX | REGENXBIO | $90.24M | $22.30M |
| MRUS | Merus | $43.95M | $7.33M |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| KZR | Kezar Life Sciences | $7.00M | - |
| KRON | Kronos Bio | $6.29M | $2.69M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| INBX | Inhibrx | $1.80M | - |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| GPCR | Structure Therapeutics | - | - |
| LIAN | LianBio | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| PASG | Passage Bio | - | - |
CRNX Revenue FAQ
What is Crinetics Pharmaceuticals’s yearly revenue?
Crinetics Pharmaceuticals's yearly revenue for 2023 was $4.01M, representing a decrease of -15.28% compared to 2022. The company's yearly revenue for 2022 was $4.74M, representing an increase of 339.42% compared to 2021. CRNX's yearly revenue for 2021 was $1.08M, representing an increase of 1418.31% compared to 2020.
What is Crinetics Pharmaceuticals’s quarterly revenue?
Crinetics Pharmaceuticals's quarterly revenue for Q1 2024 was $640K, a 100.00% increase from the previous quarter (Q4 2023), and a -76.11% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $0, a -100.00% decrease from the previous quarter (Q3 2023), and a -100.00% decrease year-over-year (Q4 2022). CRNX's quarterly revenue for Q3 2023 was $346K, a -64.98% decrease from the previous quarter (Q2 2023), and a -24.45% decrease year-over-year (Q3 2022).
What is Crinetics Pharmaceuticals’s revenue growth rate?
Crinetics Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 272.26%, and for the last 5 years (2019-2023) was 236.38%.